Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online - 110
- California: Governor Newsom announces new tax credits that will generate $2.1 billion investment in world's 4th largest economy
- New PSA Campaign to Address Black Maternal and Infant Mortality in Los Angeles County
SAN DIEGO ~ Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has appointed Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand's board.
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Emmetra Partners with Renesas to Advance Agentic AI-Powered Imaging Solutions
- Gravity to Bring 5-Minute EV Charging to 8 Sites Across Greater LA
- California: Governor Newsom issues statement on Pope Leo XIV, the first American Pope
- New poll shows high rates of employee burnout amid concerns over politics and personal finances
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
- Tessellations Appoints Luthern Williams as Head of School
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Psychological Thriller "Killing Off Connor" To Open 34th IFS Film Fest After 12-years In Post
- Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
- California businesses in near-universal compliance with prohibition of intoxicating hemp products harmful to youth
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
Filed Under: Business
0 Comments
Latest on The Californer
- Long Beach: City Celebrates Inaugural National Home Improvement Month: Love Where You Live
- California sues Trump administration for illegally withholding billions in bipartisan infrastructure funds: 'Another Trump gift to China'
- Tale of two trains: California high-speed rail leaves Texas in the dust
- California: State invests nearly $33 billion in cap-and-trade dollars to make communities cleaner and healthier
- Where AI Falls Short, Real Connections Rise—Media Outreach with Heart
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- EY US unveils Puneet Nanda of GuruNanda as an Entrepreneur Of The Year® 2025 Award Finalist
- California: Governor Newsom proclaims Children's Mental Health Awareness Week 2025
- VC Mastermind Launches: A Private Global Network and Podcast for Top-Tier Venture Capital Leaders
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Actor and Writer Ernie Rivera Launches Groundbreaking Indie Superhero Thriller, Citadel Lost, with Full Campaign and Industry Buzz
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- ViroMissile Unveils IDOV™ Platform: A Potential One-Shot Cure for Cancer
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Expert Tongue-Tie and Lip-Tie Treatment Now Available at SVPD and Orthodontics